The **bio-tech firm Ventas**, represented by its ticker $VTR, has been the subject of significant investment activity, with numerous entities buying or selling shares. Notably, **Northwest & Ethical Investments L.P.**, **Baird**, and **Korea Investment CORP** have recently increased their holdings in Ventas. The company is also in talks to acquire a **senior housing portfolio on Long Island for $600M**. Financial analysts from **Baird**, **Raymond James**, **JPMorgan**, and **RBC Capital** are maintaining a 'buy' rating for Ventas, with Baird and Morgan Stanley raising its target price to $76 and $75, respectively. The company beat **Q1 and Q2 FFO and revenue estimates**, lifting their 2025 guidance after Q2 gains. The stock gained **15.5%** year to date, indicating positive momentum. Despite some volatility, stock analyses point to mixed signals amid solid fundamentals and potential strategic crossroads. Ventas was also identified as outperforming the Real Estate sector and being a great dividend stock.
Ventas VTR News Analytics from Wed, 12 Feb 2025 08:00:00 GMT to Sun, 24 Aug 2025 00:12:40 GMT -
Rating 7
- Innovation 2
- Information 7
- Rumor 4
